EUVIMEDEUVIMED entdecken
Crossref

Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity

Mai S El-Shoukrofy, Mai E Amr, Tarek M Okda, A-Mohsen M E Omar, Omaima M AboulWafa

Bioorganic & Medicinal Chemistry · 2026

DOI: 10.1016/j.bmc.2025.118477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026. Verfasst von Mai S El-Shoukrofy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt. Electronic address: mai.elshoukrofy@alex…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Aromatase Inhibitors, Benzoxazoles. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel anti-breast cancer benzoxazoles were synthesized applying the scaffold hopping and molecular hybridization approaches. MTT assay showed that 6 and 9b were 4.5 and 2 times more potent than doxorubicin against MCF-7 cells, while 9a and 13b were 10 and 7.5 times more effective against MDA-MB-231 cells, respectively. The four compounds showed good safety profiles toward MCF-10A cells' growth. Enzyme inhibition assays identified 9b as a potent aromatase (ARO) inhibitor, exhibiting twice the potency of letrozole. 13d was more potent PI3Kα inhibitor than pictilisib, while 6, 9a, and 13b were multi-kinase inhibitors. Compound 9a was 2 and 2.5 times more potent than lapatinib against EGFRWT and EGFRL858R, besides being a selective PI3Kα/β inhibitor, surpassing pictilisib by 3 and 1.5 times, respectively. Compound 13b exhibited comparable EGFRL858R inhibition to lapatinib and outperformed pictilisib against PI3Kα, PI3Kβ, and PI3Kδ. Compound 6 showed greater ARO inhibition than letrozole, while being slightly less potent than pictilisib against PI3Kα and PI3Kβ. The four compounds downregulated p-ERK and/or p-AKT levels more effectively than letrozole or lapatinib. They elevated Beclin-1 levels and increased caspase-9 levels with 6, 9a and 9b inducing higher %total apoptosis than doxorubicin in annexin V/ propidium iodide assay. Moreover, 9a reduced cell migration and invasion percentages to 9.22 and 16.95 %, respectively, in MDA-MB-231-treated cells, thereby suppressed metastasis. Docking studies supported the in vitro enzymatic inhibition assays results. Thus, 9b and 13d are potent anti-breast cancer benzoxazoles with selective ARO and PI3kα inhibition activity, respectively, while 6, 9a, and 13b are multi-target inhibitors exhibiting other anticancer synergistic mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsAromatase InhibitorsBenzoxazolesPhosphatidylinositol 3-KinasesAromatasePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipFemaleDrug Screening Assays, AntitumorCell ProliferationMolecular StructureDose-Response Relationship, DrugMolecular Docking SimulationCell Line, Tumor

Stichwörter der Autor:innen

ApoptosisAromataseBeclin-1BenzoxazoleBreast cancerEGFRPI3K

Substanzen

ErbB ReceptorsAntineoplastic AgentsAromatase InhibitorsBenzoxazolesPhosphatidylinositol 3-KinasesAromataseEGFR protein, humanPhosphoinositide-3 Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt. Electronic address: mai.elshoukrofy@alexu.edu.eg.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Damanhour University, 22511 Damanhour, Egypt.

Zitieren

APA

El-Shoukrofy, M. S., Amr, M. E., Okda, T. M., Omar, A. M. E., & AboulWafa, O. M. (2026). Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2025.118477

Vancouver

El-Shoukrofy MS, Amr ME, Okda TM, Omar AME, AboulWafa OM. Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity. Bioorganic & Medicinal Chemistry. 2026. doi:10.1016/j.bmc.2025.118477

BibTeX
@article{ElShoukrofy2026,
  author = {El-Shoukrofy, Mai S and Amr, Mai E and Okda, Tarek M and Omar, A-Mohsen M E and AboulWafa, Omaima M},
  title = {Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2026},
  doi = {10.1016/j.bmc.2025.118477}
}
Kostenlos starten →